Literature DB >> 20714782

Meningiomas and neurofibromatosis.

Stéphane Goutagny1, Michel Kalamarides.   

Abstract

Neurofibromatosis type 2 (NF2) is a rare genetic disorder predisposing to multiple benign tumors of the nervous system. Meningiomas occur in about half of NF2 patients, and are often multiple. Patients harboring seemingly isolated multiple meningiomas should be investigated to diagnose NF2 by careful familial history collection, detailed clinical examination (skin lesions and slit lamp examination of the lens), audiovestibular testing, and fine cranio-spinal Magnetic Resonance Imaging. Somatic mosaicism is frequent in NF2 and may explain a mild phenotype as, e.g. isolated multiple meningiomas. Neurofibromatosis type 1 is not associated with an increased risk of meningioma. Whether meningiomas are part of the schwannomatosis tumor phenotype or not remains debated. Meningiomas in NF2 patients are associated with a higher risk of mortality, and their treatment is challenging, but data about natural history of meningiomas in NF2 patients in the literature are sparse. Thus, knowledge of tumor behavior is essential in slow growing tumors like meningiomas, to balance the risk of treatment against the natural history of the disease, and to evaluate the efficiency of alternative therapeutics (radiation therapy or new drugs).

Entities:  

Mesh:

Year:  2010        PMID: 20714782     DOI: 10.1007/s11060-010-0339-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas.

Authors:  J Antinheimo; H Haapasalo; M Haltia; M Tatagiba; S Thomas; A Brandis; M Sainio; O Carpen; M Samii; J Jääskeläinen
Journal:  J Neurosurg       Date:  1997-10       Impact factor: 5.115

2.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

3.  Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.

Authors:  M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone
Journal:  Neuropediatrics       Date:  2005-02       Impact factor: 1.947

4.  Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.

Authors:  A Mohyuddin; W J Neary; A Wallace; C L Wu; S Purcell; H Reid; R T Ramsden; A Read; G Black; D G R Evans
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

5.  Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors.

Authors:  Stacy Wentworth; Melva Pinn; J Daniel Bourland; Allan F Deguzman; Kenneth Ekstrand; Thomas L Ellis; Steven S Glazier; Kevin P McMullen; Michael Munley; Volker W Stieber; Stephen B Tatter; Edward G Shaw
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-05       Impact factor: 7.038

6.  Familial meningioma is not allelic to neurofibromatosis 2.

Authors:  S M Pulst; G A Rouleau; C Marineau; P Fain; J P Sieb
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

7.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

8.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

9.  Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.

Authors:  L Kluwe; V Mautner; B Heinrich; R Dezube; L B Jacoby; R E Friedrich; M MacCollin
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

10.  Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Authors:  Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini
Journal:  Brain Pathol       Date:  2007-10-09       Impact factor: 6.508

View more
  25 in total

1.  Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.

Authors:  Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2011-12-02       Impact factor: 2.802

Review 2.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

3.  Spinal meningioma in childhood: clinical features and treatment.

Authors:  Xiao-Qiang Wang; Xian-Wei Zeng; Bi-Yun Zhang; Ya-Fang Dou; Jin-Song Wu; Cheng-Chuan Jiang; Ping Zhong; Hong Chen
Journal:  Childs Nerv Syst       Date:  2011-09-25       Impact factor: 1.475

Review 4.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

Review 5.  Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes.

Authors:  Fausto J Rodriguez; Constantine A Stratakis; D Gareth Evans
Journal:  Acta Neuropathol       Date:  2011-12-31       Impact factor: 17.088

Review 6.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

7.  Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.

Authors:  Ivo S Muskens; Anna H Wu; Jacqueline Porcel; Iona Cheng; Loïc Le Marchand; Joseph L Wiemels; Veronica Wendy Setiawan
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

8.  Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.

Authors:  Stéphane Goutagny; Alpha Boubacar Bah; Dominique Henin; Béatrice Parfait; Alexis Bozorg Grayeli; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2012-06-18       Impact factor: 12.300

Review 9.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

10.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.